Ananda Developments PLC First Cannabinoid Medicines Launched (3310H)
July 27 2023 - 2:00AM
UK Regulatory
TIDMANA
RNS Number : 3310H
Ananda Developments PLC
27 July 2023
27 July 2023
ANANDA DEVELOPMENTS PLC
("Ananda" or the "Company")
First cannabinoid medicines launched
Ananda's ambition is to be a leading provider of high-quality
cannabinoid-based medicines for the treatment of complex, chronic
inflammatory pain conditions.
Highlights
-- Ananda's wholly owned subsidiary MRX Medical Limited (MRX)
has today launched its first two cannabinoid medicines MRX1 and
MRX2 on to the unlicenced medicinal products (specials) market
-- The oils will be listed on the formularies (list of
prescribable medicines) of three private pain and medical cannabis
prescribing clinics in the UK
-- MRX1 has been selected to be used in the two Phase II, double
blind, RCTs (Randomised Control Trials) run by researchers at the
university of Edinburgh
Ananda's CEO, Melissa Sturgess, commented: "We are determined to
win NHS support for our cannabinoid medicines with our rigorous
approach to formulation development, clinical trials and
traditional pharmaceutical data collection. We believe that MRX is
in the strongest position to do exactly that. With NHS endorsement
we can bring these medicines to the millions of people who need
them and deliver revenues to Ananda."
Following the signing of the final manufacturing agreement with
MRX's contract manufacturing organisation (CMO) on 26 July 2023
after market close, Ananda is pleased to announce that as of today
both MRX1 and MRX2 are now available for Specialist doctors to
prescribe to their patients.
Both MRX1 and MRX2, as well as a to-be released formulation MRX3
are patent pending. There is a fourth pending patent application
which covers MRX's proprietary method for formulating these
medicines. MRX1 is also to be used in two Investigative Medicinal
Products (IMPs), which will be used in two Phase II RCTs. The RCTs
are investigating the efficacy of cannabidiol in treating
chemotherapy induced peripheral neuropathy (CIPN) and
endometriosis. Both trials are being conducted by world leading
clinician investigators at the University of Edinburgh and
collectively have received commitments for GBP1.55m of non-dilutive
grant funding.
For all prescriber and clinic enquiries related to MRX medicines
please contact Jack Morgan at jack.morgan@anandadevelopments.com.
Please also visit the MRX website, www.mrxmedical.com.
-Ends-
The Directors of the Company accept responsibility for the
contents of this announcement.
ANANDA DEVELOPMENTS PLC +44 (0)7463 686 497
ir@anandadevelopments.com
Chief Executive Officer
Melissa Sturgess
Finance Director
Jeremy Sturgess-Smith
SP ANGEL CORPORATE FINANCE
LLP +44 (0)20 3470 0470
Corporate Finance
Richard Morrison
Harry Davies-Ball
Corporate Broking
Abigail Wayne
Rob Rees
About Ananda Developments
Ananda is an AQSE-listed company whose ambition is to be a
leading provider of cannabinoid-based medicines for the treatment
of complex, chronic inflammatory pain conditions.
To stay abreast of the latest developments at Ananda, we
encourage you to follow our social media channels which are:
-- Instagram: https://instagram.com/anandadevelopments?igshid=YmMyMTA2M2Y=
-- LinkedIn: https://www.linkedin.com/company/anadevelopments/
-- Twitter: https://twitter.com/anandaplc?s=21&t=9yeIC_xYCfzgDn7j26sfuA
For more information, please visit:
https://anandadevelopments.com/
Market Abuse Regulation (MAR) Disclosure
The information contained within this announcement is deemed by
the Company to constitute inside information. Upon the publication
of this announcement via a Regulatory Information Service, this
inside information is now considered to be in the public do
main.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCBQLLLXDLFBBE
(END) Dow Jones Newswires
July 27, 2023 02:00 ET (06:00 GMT)
Ananda Developments (AQSE:ANA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Ananda Developments (AQSE:ANA)
Historical Stock Chart
From Jul 2023 to Jul 2024